<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336429">
  <stage>Registered</stage>
  <submitdate>18/01/2011</submitdate>
  <approvaldate>20/01/2011</approvaldate>
  <actrnumber>ACTRN12611000074998</actrnumber>
  <trial_identification>
    <studytitle>The effects of adjuvant Tualang honey therapy on disease activity markers in systemic lupus erythematosus patients</studytitle>
    <scientifictitle>A prospective, unblinded, randomised study to evaluate the effect of adjuvant Tualang honey therapy on disease activity markers in systemic lupus erythematosus patients</scientifictitle>
    <utrn>U1111-1119-0723</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>systemic lupus erythematosus</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Tualang honey 20 gm twice a day
Duration 6 months</interventions>
    <comparator>active control : standard treatment
maintenance treatment with low dose steroid ( 10 mg ), alone or in combination with immunosuppressive drugs (cyclophosphomide 25 - 50 mg or azathioprine 50 - 100 mg maintenance treatment )</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>reduction of SLEDAI score in the honey group compared to non honey group</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>increase in complement level ( enzyme cascade to prevent infection ) in the honey group compared to non honey group.
Complement level is measured by peripheral blood</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>SLE patients fulfilled 4 out of 11 ARA criteria
on low dose prednisolone alone or combination with other immunosuppressive drugs and / or either cyclophosphomide or azathioprine maintenance treatment</inclusivecriteria>
    <inclusiveminage>13</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients who were diabetic, pregnant, suffering from chronic renal failure, cancer, HIV and allergic to honey</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>19/10/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kelantan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>School of Medical Sciences, Universiti Sains Malaysia</primarysponsorname>
    <primarysponsoraddress>Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan</primarysponsoraddress>
    <primarysponsorcountry>Malaysia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>School of Medical Sciences, Universiti Sains Malaysia</fundingname>
      <fundingaddress>Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan</fundingaddress>
      <fundingcountry>Malaysia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare the effects of adjuvant honey therapy versus conventional immunosuppressive therapy alone on disease activity based on disease activity index ( SLEDAI ) score, complement level, ANA and dsDNA in systemic lupus erytematosis patients</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Clinical Sciences, Research Platform Office</ethicname>
      <ethicaddress>Universiti Sains Malaysia
Health Campus, 16150
Kubang Kerian, Kelantan</ethicaddress>
      <ethicapprovaldate>18/10/2009</ethicapprovaldate>
      <hrec>1001/PPSP/81202016</hrec>
      <ethicsubmitdate />
      <ethiccountry>Malaysia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Wan Syamimee Wan Ghazali</name>
      <address>Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan</address>
      <phone>+6 09 7673000</phone>
      <fax>+6 09 7673949</fax>
      <email>syamimee@kb.usm.my</email>
      <country>Malaysia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Wan Syamimee Wan Ghazali</name>
      <address>Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan</address>
      <phone>+6 09 7673000</phone>
      <fax>+6 09 7673949</fax>
      <email>syamimee@kb.usm.my</email>
      <country>Malaysia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Wan Syamimee Wan Ghazali</name>
      <address>Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan</address>
      <phone>+6 09 7673000</phone>
      <fax>+6 09 7673949</fax>
      <email>syamimee@kb.usm.my</email>
      <country>Malaysia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>